Chandra Briggman is leaving Richmond’s Activation Capital

Chandra Briggman is exiting her role as president and CEO of Richmond’s Activation Capital.

The independent authority of Virginia that promotes research, commercialization and innovation ecosystem development in the Richmond region said Monday that Briggman is leaving “to pursue new opportunities to build innovation ecosystems and drive economic development.”

She’s been in the role a little more than four years, joining in June 2020 from a job directing Venture Café Cambridge in Massachusetts, a similar organization that focuses on enhancing and accelerating innovation across New England.

Briggman’s last day with Activation Capital was not revealed. The organization said a search for a permanent executive will be conducted, though no timetable was given.

“The opportunity to contribute to Activation Capital and the Central Virginia community has been a highlight of my career,” Briggman said in a statement. “It gave me an opportunity to sharpen the organization’s strategy, secure the growth capital necessary to flourish and align every action with a mission-centric outcome. Together, we built a team of experts who are focused on execution and excellence during the next phase of Activation Capital. My goal was always to create the team, prove our model, and then transition to the next opportunity to build.”

Activation Capital credits Briggman with implementing a new strategy focused on growing the region’s innovation economy through development, space-making and venture development and raising more than $50 million in funding for that work. Briggman has also been co-leader of the Alliance for Building Better Medicine, a coalition of Richmond and Petersburg organizations working together to build a research and manufacturing hub for essential medicines and their ingredients. In 2022, the group won a $53 million grant through the White House’s Build Back Better Regional Challenge. It also scored a $1 million grant from the National Science Foundation.

Activation Capital also operates the 34-acre VA Bio+Tech Park in downtown Richmond, and Briggman has led the charge for a new innovation center there.

“Chandra is a builder and visionary, and as a result, Activation Capital has grown to be something much bigger than it was before she joined,” Michael Rao, chairman of the Virginia Biotechnology Research Partnership Authority board and Virginia Commonwealth University president, said in a statement.

Learn more here.

Recent News


Capra Biosciences Lands $7.5 Million Project Agreement To Demonstrate Platform To Rapidly Scale Pharmaceutical Ingredient Manufacturing

Many ingredients that make up the pharmaceuticals Americans rely on are manufactured overseas. When supply chain issues or shortages occur, as witnessed during the COVID pandemic, it can negatively impact millions of Americans and affect national security. The White House issued an Executive Order in 2022 to stimulate U.S. biomanufacturing. Increasing American biomanufacturing, will provide


Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity

AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients. Omega3 lipids called polyunsaturated fatty acids (PUFAs) that are found in microscopic shrimp-like crustaceans called Krill from the waters around Antarctica are key to maintaining a low inflammatory state.  Some


Inorganic Ventures acquires PURE Analytical Laboratories, Combining Unique Capabilities for Precision Manufacturing

Two privately held specialty chemical firms that provide high-purity materials and services for chemical applications, from renewable energy to food and beverages and consumer safety, are combining their capabilities to serve new and expanding precision markets. IV Labs Inc., the parent company of Inorganic Ventures, has acquired PURE Analytical Laboratories, one of the few companies that